Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2008

01.03.2008 | Original Article

I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study

verfasst von: Denis Agostini, Hein J. Verberne, Wolfgang Burchert, Juhani Knuuti, Pavol Povinec, Gianmario Sambuceti, Mustafa Unlu, Montserrat Estorch, Gopa Banerjee, Arnold F. Jacobson

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Single-center experiences have shown that myocardial meta-iodobenzylguanidine (mIBG) uptake has prognostic value in heart failure (HF) patients. To verify these observations using a rigorous clinical trial methodology, a retrospective review and prospective quantitative reanalysis was performed on a series of cardiac 123I-mIBG scans acquired during a 10-year period at six centers in Europe.

Methods

123I-mIBG scans obtained on 290 HF patients [(262 with left ventricular ejection fraction (LVEF) < 50%)] from 1993 to 2002 were reanalyzed using a standardized methodology to determine the heart-to-mediastinum ratio (H/M) on delayed planar images. All image results were verified by three independent reviewers. Major cardiac events [MCEs; cardiac death, cardiac transplant, potentially fatal arrhythmia (including implantable cardioverter-defibrillator discharge)] during 24-month follow-up were confirmed by an adjudication committee.

Results

MCEs occurred in 67 patients (26%): mean H/M ratio was 1.51 ± 0.30 for the MCE group and 1.97 ± 0.54 for the non-MCE group (p < 0.001). Two-year event-free survival using an optimum H/M ratio threshold of 1.75 was 62% for H/M ratio less than 1.75, 95% for H/M ratio greater than or equal to 1.75 (p < 0.0001). Logistic regression showed H/M ratio and LVEF as the only significant predictors of MCE. Using the lower and upper H/M quartiles of 1.45 and 2.17 as high- and very low-risk thresholds, 2-year event-free survival rates were 52% and 98%, respectively. Among patients with LVEF ≤ 35% and H/M ≥ 1.75 (n = 73), there were nine MCEs because of progressive HF and only one because of an arrhythmia.

Conclusion

Application of a clinical trial methodology via the retrospective reanalysis of 123I-mIBG images confirms the previously reported prognostic value of this method in HF patients, including potential identification of a quantitative threshold for low risk for cardiac mortality and potentially fatal ventricular arrhythmias.
Literatur
1.
Zurück zum Zitat Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115–40.PubMedCrossRef Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115–40.PubMedCrossRef
2.
Zurück zum Zitat Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208–25.PubMed Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208–25.PubMed
3.
Zurück zum Zitat Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151.PubMedCrossRef Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151.PubMedCrossRef
4.
Zurück zum Zitat Ehlert FA, Cannom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell L, et al. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmia: differences in presentation and outcome in the AVID registry. Am Heart J. 2001;142:816–22.PubMedCrossRef Ehlert FA, Cannom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell L, et al. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmia: differences in presentation and outcome in the AVID registry. Am Heart J. 2001;142:816–22.PubMedCrossRef
5.
Zurück zum Zitat Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedCrossRef Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedCrossRef
6.
Zurück zum Zitat Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef
7.
Zurück zum Zitat Skrabal MZ, Stading JA, Hilleman DE, Behmer-Miller KA. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy. 2000;20:787–804.PubMedCrossRef Skrabal MZ, Stading JA, Hilleman DE, Behmer-Miller KA. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy. 2000;20:787–804.PubMedCrossRef
8.
Zurück zum Zitat Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J. 2005;149:1020–34.PubMedCrossRef Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J. 2005;149:1020–34.PubMedCrossRef
9.
Zurück zum Zitat Bukharovich IF, Kukin M. Optimal medical therapy for heart failure. Prog Cardiovasc Dis. 2006;48:372–85.PubMedCrossRef Bukharovich IF, Kukin M. Optimal medical therapy for heart failure. Prog Cardiovasc Dis. 2006;48:372–85.PubMedCrossRef
10.
Zurück zum Zitat Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.PubMedCrossRef Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.PubMedCrossRef
11.
Zurück zum Zitat Gehi AK, Stein RH MD, Metz LD, Gomes JA. Microvolt T-Wave Alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol. 2005;46:75–82.PubMedCrossRef Gehi AK, Stein RH MD, Metz LD, Gomes JA. Microvolt T-Wave Alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol. 2005;46:75–82.PubMedCrossRef
12.
Zurück zum Zitat Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep. 2006;8:131–8.PubMedCrossRef Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep. 2006;8:131–8.PubMedCrossRef
13.
Zurück zum Zitat Muller KD, Jakob H, Neuzner J, Grebe SF, Schlepper M, Pitschner HF. 123I-metaiodobenzylguanidine scintigraphy in the detection of irregular regional sympathetic innervation in long QT syndrome. Eur Heart J. 1993;14:316–25.PubMed Muller KD, Jakob H, Neuzner J, Grebe SF, Schlepper M, Pitschner HF. 123I-metaiodobenzylguanidine scintigraphy in the detection of irregular regional sympathetic innervation in long QT syndrome. Eur Heart J. 1993;14:316–25.PubMed
14.
Zurück zum Zitat Kammerling JJ, Green FJ, Watanabe AM, Inoue H, Barber MJ, Henry DP, et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation. 1987;76:383–93.PubMed Kammerling JJ, Green FJ, Watanabe AM, Inoue H, Barber MJ, Henry DP, et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation. 1987;76:383–93.PubMed
15.
Zurück zum Zitat Wafelman AR. Metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545–59.PubMedCrossRef Wafelman AR. Metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545–59.PubMedCrossRef
16.
Zurück zum Zitat Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed
17.
Zurück zum Zitat Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625–36.PubMed Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625–36.PubMed
18.
Zurück zum Zitat Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed
19.
Zurück zum Zitat Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, et al. Sympathetic nerve alterations assessed with 123I-mIBG in the failing human heart. J Nucl Med. 1999;40:224–31.PubMed Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, et al. Sympathetic nerve alterations assessed with 123I-mIBG in the failing human heart. J Nucl Med. 1999;40:224–31.PubMed
20.
Zurück zum Zitat Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed
21.
Zurück zum Zitat Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113–21.PubMedCrossRef Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113–21.PubMedCrossRef
22.
Zurück zum Zitat Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–66.PubMedCrossRef Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–66.PubMedCrossRef
23.
Zurück zum Zitat Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-mIBG scintigraphic study. J Nucl Med. 2000;41:845–51.PubMed Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-mIBG scintigraphic study. J Nucl Med. 2000;41:845–51.PubMed
24.
Zurück zum Zitat Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757–67.PubMed Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757–67.PubMed
25.
Zurück zum Zitat Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279–85.PubMed Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279–85.PubMed
26.
Zurück zum Zitat Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. A prospective study. J Am Coll Cardiol. 2003;41:231–8.PubMedCrossRef Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. A prospective study. J Am Coll Cardiol. 2003;41:231–8.PubMedCrossRef
27.
Zurück zum Zitat Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155–63.PubMed Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155–63.PubMed
28.
Zurück zum Zitat Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186–94.PubMedCrossRef Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186–94.PubMedCrossRef
29.
Zurück zum Zitat Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 mIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J.Nucl Cardiol. 2003;10:121–31.PubMedCrossRef Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 mIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J.Nucl Cardiol. 2003;10:121–31.PubMedCrossRef
30.
Zurück zum Zitat Paul M, Schafers M, Kies P, Acil T, Schafers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging. 2006;33:866–70.PubMedCrossRef Paul M, Schafers M, Kies P, Acil T, Schafers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging. 2006;33:866–70.PubMedCrossRef
31.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–235.CrossRef Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–235.CrossRef
32.
Zurück zum Zitat Estorch M, Flotats A, Serra-Grima R, Mari C, Prat T, Martin JC, et al. Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischaemic heart disease. Eur J Nucl Med. 2000;27:333–9.PubMedCrossRef Estorch M, Flotats A, Serra-Grima R, Mari C, Prat T, Martin JC, et al. Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischaemic heart disease. Eur J Nucl Med. 2000;27:333–9.PubMedCrossRef
33.
Zurück zum Zitat Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353–8.PubMedCrossRef Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353–8.PubMedCrossRef
34.
Zurück zum Zitat Parthenakis FI, Prassopoulos VK, Koukouraki SI, Zacharis EA, Diakakis GF, Karkavitsas NK, et al. Segmental pattern of myocardial sympathetic denervation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and myocardial perfusion abnormalities. J Nucl Cardiol. 2002;9:15–22.PubMedCrossRef Parthenakis FI, Prassopoulos VK, Koukouraki SI, Zacharis EA, Diakakis GF, Karkavitsas NK, et al. Segmental pattern of myocardial sympathetic denervation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and myocardial perfusion abnormalities. J Nucl Cardiol. 2002;9:15–22.PubMedCrossRef
35.
Zurück zum Zitat Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by 123I-metaiodobenzylguanidine myocardial scintigraphy. Circulation. 1997;96:821–6.PubMed Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by 123I-metaiodobenzylguanidine myocardial scintigraphy. Circulation. 1997;96:821–6.PubMed
36.
Zurück zum Zitat Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–6.PubMedCrossRef Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–6.PubMedCrossRef
37.
Zurück zum Zitat Zhou X-H, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. New York: Wiley; 2002. Zhou X-H, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. New York: Wiley; 2002.
38.
Zurück zum Zitat Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591–611. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591–611.
39.
Zurück zum Zitat Manrique A, Bernard M, Dronne F, Vera P, Bauer F, Grollier G, et al. Prognostic value of sympathetic innervation, left and right ejection fraction and LV asynchrony in dilated cardiomyopathy (Abstr). Eur J Nucl Med Mol Imaging. 2006;33:S185.CrossRef Manrique A, Bernard M, Dronne F, Vera P, Bauer F, Grollier G, et al. Prognostic value of sympathetic innervation, left and right ejection fraction and LV asynchrony in dilated cardiomyopathy (Abstr). Eur J Nucl Med Mol Imaging. 2006;33:S185.CrossRef
40.
Zurück zum Zitat Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587–602.PubMedCrossRef Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587–602.PubMedCrossRef
Metadaten
Titel
I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study
verfasst von
Denis Agostini
Hein J. Verberne
Wolfgang Burchert
Juhani Knuuti
Pavol Povinec
Gianmario Sambuceti
Mustafa Unlu
Montserrat Estorch
Gopa Banerjee
Arnold F. Jacobson
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0639-3

Weitere Artikel der Ausgabe 3/2008

European Journal of Nuclear Medicine and Molecular Imaging 3/2008 Zur Ausgabe